Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Haier Smart Home Sees Profit Drop as Revenue Grows
Trending in China: Can You Stop People Giving ‘Too Much’ Money to Their Favorite Live-Streamers?
Trending in China: Concerns Over Traditional Chinese Comedy ‘Selling Out’ In the Digital Age
ByteDance Doubles Down On Education
Chinese Biotech Firm Gracell Nets $100m From Wellington, OrbiMed, Others
Alibaba’s Hometown Could Become First in China to Issue Facial Recognition Ban
Battery and Hybrid Cars Will Dominate China’s Roads in 15 Years
Trending in China: Do The Sins Of The Father Fall On Their Sons? Social Media Lambast Pop Star with ‘Deadbeat’ Dad
Chinese Electronics Panel Maker CSOT Reports Profit Growth as Demand Soars
Xiaomi Invests in Home Improvement Firm Amid Push into Internet of Things
TikTok Escalates Patent Fight With Triller Amid Sale Talks
Chinese Self-Heating Hot Pot Brand Zihaiguo Nets Over $50m in Series C Round Led by CICC
Xiaomi Leads India’s Smartphone Market with 26.1% Share
Trending in China: Are China’s Blue-Collar Wages Really Higher Than Graduate Salaries?
Trending in China: An End to Spam Calls? Real Estate Company to Give Money to Anyone Who Receives One
Trending in China: Patriotic War Film Overpowers Foreign-Made Feature, But Not Everyone Is Impressed
Shopify Partners with TikTok to Drive Online Sales
Lawson Tests Next Step of Convenience Store Evolution in China
PUBG Creator Krafton Hires Bankers for Possible Record IPO
Mobile Browser Crackdown Ensnares Big Names
Chinese Drug Manufacturer InventisBio Bags $147m Led by Hillhouse Capital

By DealStreetAsia / Sep 29, 2020 12:43 PM / Finance

Photo: VCG

Photo: VCG

Clinical stage, small molecule drugs maker InventisBio Inc., has garnered 1 billion yuan ($147 million) in a Series D funding round led by venture capital firm Hillhouse Capital.

New investors who participated in the round included Qiming Venture Partners, MatrixPartners China, Hong Kong-based investment firm Janchor Partners, healthcare-focused AIHC Capital, DYEE Capital, and Utrust’s asset manager E Fund, InventisBio announced on Monday.

The round also saw participation from returning backers Lilly Asia Ventures (LAV), New York-based healthcare fund manager OrbiMed Asia, China Merchants Bank’s CMB International, Pudong Innotek, and China-centered AdvanTech Capital.

LAV is a long-term investor in InventisBio.

In March 2019, LAV had partnered with OrbiMed, CMB International, Pudong Innotek, and AdvanTech Capital to collectively infuse $70 million in InventisBio’s Series C round. Prior to that, LAV along with OrbiMed had invested $19 million in the company’s Series B round in 2017. It had also partnered state-owned Sinopharm Capital to invest $11 million in InventisBio’s Series A round in 2016.

Beijing-based financial institution China Renaissance served as the financial advisor for the latest funding.

Started in 2013 in Shanghai by Dr. Yaolin Wang, InventisBio develops safe and affordable immunotherapies and drugs for oncology and metabolic diseases such as breast cancer, lung cancer, and gout.

“The new investment will accelerate the development of our clinical candidates into phase 2 trials and help us develop first-in-class drug candidates into clinical stage,” said Dr. Yaolin Wang, InventisBio chairman and CEO, in the statement. “Our goal is to develop innovative drugs with our own intellectual property rights, to achieve global drug approvals based on international multi-center clinical trials for diseases with unmet medical needs.”

The fresh proceeds will be used to support drug candidates in phase II clinical trials in China and the US, fund the clinical development of new drugs globally, and also to expand the team, it said.

Related: Hillhouse’s Big Biotech Bet Hits a Wall Amid Tightening Rules


Share this article
Open WeChat and scan the QR code